Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer

Figures & data

Table 1. Baseline characteristics in BPH and incidental PCa.

	BPH	PCa		High-risk PCa
	n = 613	n = 41	p	n = 16	p^a
Age, years, mean ± SD	70 ± 7	70 ± 7	.800	71 ± 8	.768
BMI, kg/m^2, mean ± SD	23.1 ± 2.8	23.7 ± 2.6	.171	23.9 ± 2.7	.239
PSA, ng/mL, median (interquartile range)	6.10 (3.59–10.50)	6.71 (5.12–13.00)	.073	6.48 (5.65–11.06)	.152
Preoperative PV, mL, median (interquartile range)	66 (50–90)	81 (54–100)	.069	90 (54–103)	.124
Smoking	240 (39)	20 (48)	.223	9 (56)	.167
Hypertension	236 (39)	19 (46)	.319	6 (38)	.935
Diabetes	79 (13)	8 (20)	.227	5 (31)	.033
Dyslipidemia	96 (16)	10 (24)	.142	4 (25)	.301
Previous biopsy	234 (38)	19 (46)	.299	8 (50)	.337
Previous dutasteride therapy	79 (13)	2 (5)	.216	0 (0)	.243

Values are n (%) unless otherwise stated.

BPH: benign prostate hyperplasia; PCa: prostate cancer.

^a Patients with high-risk PCa compared to those with BPH.

Table 2. Logistic regression analysis predicting prostate cancer.

	Odds ratio	95% confidence interval	p
BMI, per 1 kg/m^2	1.072	0.956–1.201	.235
PSA, per 1 ng/mL	1.019	0.984–1.055	.291
Preoperative PV, per 1 mL	1.004	0.996–1.012	.306
Dyslipidemia	1.711	0.800–3.659	.166

Table 3. Logistic regression analysis predicting high-risk prostate cancer.

	Odds ratio	95% confidence interval	p
PSA, per 1 ng/mL	1.005	0.948–1.066	.860
Preoperative PV, per 1 mL	1.008	0.996–1.020	.214
Smoking	2.112	0.769–5.802	.147
Diabetes	3.154	1.055–9.433	.040